KR20080109085A - Ｇ-단백질 결합 수용체(ｇｐｒ119) 작용제로서의 아제티딘 유도체 - Google Patents
Ｇ-단백질 결합 수용체(ｇｐｒ119) 작용제로서의 아제티딘 유도체 Download PDFInfo
- Publication number
- KR20080109085A KR20080109085A KR1020087027643A KR20087027643A KR20080109085A KR 20080109085 A KR20080109085 A KR 20080109085A KR 1020087027643 A KR1020087027643 A KR 1020087027643A KR 20087027643 A KR20087027643 A KR 20087027643A KR 20080109085 A KR20080109085 A KR 20080109085A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutically acceptable
- alkyl
- acceptable salt
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- OKSRCHHNHPVNNZ-UHFFFAOYSA-O CC(CC1)C=CC1Oc1ccc(CN(C2)CC2Oc(cc2)ccc2-c(cc2)ccc2S(C)([OH2+])=O)cc1 Chemical compound CC(CC1)C=CC1Oc1ccc(CN(C2)CC2Oc(cc2)ccc2-c(cc2)ccc2S(C)([OH2+])=O)cc1 OKSRCHHNHPVNNZ-UHFFFAOYSA-O 0.000 description 1
- SYVPUGOJMOLVGP-UHFFFAOYSA-O CS(C1=CC=C(c(cc2)ccc2OC2CN(Cc(cc3)ccc3OC3C=CC=CC3)C2)NC1)([OH2+])=O Chemical compound CS(C1=CC=C(c(cc2)ccc2OC2CN(Cc(cc3)ccc3OC3C=CC=CC3)C2)NC1)([OH2+])=O SYVPUGOJMOLVGP-UHFFFAOYSA-O 0.000 description 1
- JKKQKXUAEIZMSX-UHFFFAOYSA-N CS(c(cc1)ncc1-c(cc1)ccc1OC1CN(Cc(cc2)ccc2OC(F)(F)F)C1)=O Chemical compound CS(c(cc1)ncc1-c(cc1)ccc1OC1CN(Cc(cc2)ccc2OC(F)(F)F)C1)=O JKKQKXUAEIZMSX-UHFFFAOYSA-N 0.000 description 1
- WXPRCKQCESNJFC-UHFFFAOYSA-N CS(c(cc1)ncc1-c(cc1)ccc1OC1CN(Cc2ccccc2)C1)=O Chemical compound CS(c(cc1)ncc1-c(cc1)ccc1OC1CN(Cc2ccccc2)C1)=O WXPRCKQCESNJFC-UHFFFAOYSA-N 0.000 description 1
- YNLVFSBJFIXWRG-UHFFFAOYSA-N Cc1cc(CN(C2)CC2Oc(cc2)ccc2-c(cc2)cnc2S(C)=O)ccc1 Chemical compound Cc1cc(CN(C2)CC2Oc(cc2)ccc2-c(cc2)cnc2S(C)=O)ccc1 YNLVFSBJFIXWRG-UHFFFAOYSA-N 0.000 description 1
- GZPSUGVXNAHNPR-UHFFFAOYSA-N N#Cc(cc1)ccc1-c(cc1)ccc1OC1CN(Cc(cc2)ccc2Oc2ccccc2)C1 Chemical compound N#Cc(cc1)ccc1-c(cc1)ccc1OC1CN(Cc(cc2)ccc2Oc2ccccc2)C1 GZPSUGVXNAHNPR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0607196.3 | 2006-04-11 | ||
| GBGB0607196.3A GB0607196D0 (en) | 2006-04-11 | 2006-04-11 | G-protein coupled receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080109085A true KR20080109085A (ko) | 2008-12-16 |
Family
ID=36539676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087027643A Ceased KR20080109085A (ko) | 2006-04-11 | 2007-04-11 | Ｇ-단백질 결합 수용체(ｇｐｒ119) 작용제로서의 아제티딘 유도체 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090281076A1 (enExample) |
| EP (1) | EP2010485B1 (enExample) |
| JP (1) | JP2009533410A (enExample) |
| KR (1) | KR20080109085A (enExample) |
| CN (1) | CN101466667A (enExample) |
| AU (1) | AU2007235674A1 (enExample) |
| BR (1) | BRPI0709953A2 (enExample) |
| CA (1) | CA2648687A1 (enExample) |
| GB (1) | GB0607196D0 (enExample) |
| MX (1) | MX2008012946A (enExample) |
| NO (1) | NO20084364L (enExample) |
| NZ (1) | NZ571962A (enExample) |
| WO (1) | WO2007116230A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
| CA2697551C (en) | 2007-09-20 | 2013-03-12 | Irm Llc | Piperidine derivatives as modulators of gpr119 activity |
| GB0720390D0 (en) * | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) * | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| US20110166176A1 (en) * | 2008-02-22 | 2011-07-07 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| CN102007100A (zh) * | 2008-02-22 | 2011-04-06 | Irm责任有限公司 | 作为gpr119活性调控剂的化合物和组合物 |
| JP2011516557A (ja) * | 2008-04-07 | 2011-05-26 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| MX2011000664A (es) * | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| WO2010059390A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Modulators of serotonin receptor |
| US8642583B2 (en) | 2008-10-30 | 2014-02-04 | Janssen Pharmaceutica Nv | Serotonin receptor modulators |
| WO2010084512A1 (en) | 2008-12-24 | 2010-07-29 | Cadila Healthcare Limited | Novel oxime derivatives |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| EA201200570A1 (ru) * | 2009-10-09 | 2012-11-30 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности gpr119 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| EP2616441B1 (en) * | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| AU2011311183B2 (en) | 2010-10-08 | 2014-09-25 | Cadila Healthcare Limited | Novel GPR 119 agonists |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| WO2012066077A1 (en) | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
| EP2643311A1 (en) | 2010-11-26 | 2013-10-02 | Lupin Limited | Bicyclic gpr119 modulators |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HK1210825A1 (en) | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| CN106749179A (zh) * | 2015-03-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途 |
| CN104725354A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺和哌啶结构化合物及其用途 |
| CN104788424A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5130309A (en) * | 1991-04-12 | 1992-07-14 | A. H. Robins Company, Incorporated | Aryloxy and aryloxyalklazetidines as antiarrhythmic and anticonvulsant agents |
| WO1998034919A1 (en) * | 1997-02-10 | 1998-08-13 | Pfizer Products Inc. | 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines |
| TW200305395A (en) * | 2002-03-15 | 2003-11-01 | Novartis Ag | Organic compounds |
| SE0301368D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| BRPI0418149A (pt) * | 2003-12-24 | 2007-04-17 | Prosidion Ltd | derivados heterocìclicos como agonistas do receptor de gprc |
| MX2007003319A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| AP2007004047A0 (en) * | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| AR053712A1 (es) * | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
-
2006
- 2006-04-11 GB GBGB0607196.3A patent/GB0607196D0/en not_active Ceased
-
2007
- 2007-04-11 CN CNA2007800217539A patent/CN101466667A/zh active Pending
- 2007-04-11 KR KR1020087027643A patent/KR20080109085A/ko not_active Ceased
- 2007-04-11 JP JP2009504834A patent/JP2009533410A/ja active Pending
- 2007-04-11 US US12/296,717 patent/US20090281076A1/en not_active Abandoned
- 2007-04-11 WO PCT/GB2007/050190 patent/WO2007116230A1/en not_active Ceased
- 2007-04-11 CA CA002648687A patent/CA2648687A1/en not_active Abandoned
- 2007-04-11 AU AU2007235674A patent/AU2007235674A1/en not_active Abandoned
- 2007-04-11 BR BRPI0709953-3A patent/BRPI0709953A2/pt not_active IP Right Cessation
- 2007-04-11 NZ NZ571962A patent/NZ571962A/en not_active IP Right Cessation
- 2007-04-11 EP EP07733612A patent/EP2010485B1/en active Active
- 2007-04-11 MX MX2008012946A patent/MX2008012946A/es active IP Right Grant
-
2008
- 2008-10-17 NO NO20084364A patent/NO20084364L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ571962A (en) | 2011-07-29 |
| CN101466667A (zh) | 2009-06-24 |
| EP2010485A1 (en) | 2009-01-07 |
| JP2009533410A (ja) | 2009-09-17 |
| MX2008012946A (es) | 2008-11-28 |
| CA2648687A1 (en) | 2007-10-18 |
| GB0607196D0 (en) | 2006-05-17 |
| NO20084364L (no) | 2008-10-31 |
| EP2010485B1 (en) | 2012-10-17 |
| WO2007116230A8 (en) | 2007-12-27 |
| BRPI0709953A2 (pt) | 2011-08-02 |
| WO2007116230A1 (en) | 2007-10-18 |
| AU2007235674A1 (en) | 2007-10-18 |
| US20090281076A1 (en) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2010485B1 (en) | Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists | |
| US8173807B2 (en) | Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists | |
| US11759462B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
| US20100286110A1 (en) | Azetidinyl g-protein coupled receptor agonists | |
| EP2013201B1 (en) | Heterocyclic gpcr agonists | |
| US8207147B2 (en) | Heterocyclic derivatives as GPCR receptor agonists | |
| EP4227299A1 (en) | Benzimidazolone glp-1 receptor agonist and use thereof | |
| US20110059942A1 (en) | Azetidinyl G-Protein Coupled Receptor Agonists | |
| KR20070091038A (ko) | Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도 | |
| US20090221644A1 (en) | Gpcr Agonists | |
| KR20090104092A (ko) | 피페리딘 ｇｐｃｒ 효능제 | |
| JP2010514831A (ja) | ピペリジンｇｐｃｒアゴニスト | |
| KR20060019587A (ko) | 치환된 3-알킬 및 3-알케닐 아제티딘 유도체 | |
| KR20080027908A (ko) | Ｇｐｃｒ 효능제 | |
| JP2010514832A (ja) | ピペリジンｇｐｃｒアゴニスト | |
| JP2010514830A (ja) | ピペリジンｇｐｃｒアゴニスト | |
| KR20080110809A (ko) | 콜레시스토키닌-1 수용체 조절제로서의 치환된 이미다졸 4-카복스아미드 | |
| JP2012520282A (ja) | 代謝障害治療のための化合物 | |
| KR20090064458A (ko) | 봄베신 수용체 아형-3 조절제로서의 치환된 이미다졸 | |
| WO2012006955A1 (en) | Compounds for treatment of metabolic disorders | |
| HK1092139A (en) | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20081111 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20120412 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130827 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20131128 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130827 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |